The Chicago Entrepreneur

Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion. 

Previous post Online casinos will generate more revenue in the UK this year than in the US, new data reveals
Next post Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction